| Q36410082 | A Photo-Crosslinkable Biotin Derivative of the Phosphoantigen (E)-4-Hydroxy-3-Methylbut-2-Enyl Diphosphate (HMBPP) Activates Vγ9Vδ2 T Cells and Binds to the HMBPP Site of BTN3A1. |
| Q52731753 | A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells. |
| Q36674426 | A new effect of IL-4 on human γδ T cells: promoting regulatory Vδ1 T cells via IL-10 production and inhibiting function of Vδ2 T cells |
| Q38756878 | A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. |
| Q46131239 | A regulatory cross-talk between Vgamma9Vdelta2 T lymphocytes and mesenchymal stem cells |
| Q34002174 | A role for the mevalonate pathway in the induction of subtype cross-reactive immunity to influenza A virus by human gammadelta T lymphocytes |
| Q55339238 | ABCA1, apoA-I, and BTN3A1: A Legitimate Ménage à Trois in Dendritic Cells. |
| Q40596798 | ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing |
| Q57309120 | Activated gammadelta T cells express the natural cytotoxicity receptor natural killer p 44 and show cytotoxic activity against myeloma cells |
| Q35222179 | Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer |
| Q90398665 | Activation of Human γδ T Cells: Modulation by Toll-Like Receptor 8 Ligands and Role of Monocytes |
| Q54373964 | Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). |
| Q38730126 | Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer |
| Q99571885 | Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study |
| Q40146526 | Adoptively transferred Vγ9Vδ2 T cells show potent antitumor effects in a preclinical B cell lymphomagenesis model |
| Q38198742 | Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer |
| Q90090369 | Alpaca (Vicugna pacos), the first nonprimate species with a phosphoantigen-reactive Vγ9Vδ2 T cell subset |
| Q40514344 | Alpha-bisabolol, not a matter for cancer therapy. Commentary: "Research on the immunosuppressive activity of ingredients contained in sunscreens" |
| Q51145613 | Alteration of Mevalonate Pathway in Rat Splenic Lymphocytes: Possible Role in Cytokines Secretion Regulated by L-Theanine. |
| Q37012505 | Altered cord blood gammadelta T cell repertoire in Nigeria: possible impacts of environmental factors on neonatal immunity |
| Q38798990 | Aminobisphosphonates Synergize with Human Cytomegalovirus To Activate the Antiviral Activity of Vγ9Vδ2 Cells |
| Q39158802 | Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor Vδ 2 T lymphocytes in non-Hodgkin lymphomas. |
| Q90616712 | An innate-like Vδ1+ γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer |
| Q36759195 | Analysis of Immune Cells from Human Mammary Ductal Epithelial Organoids Reveals Vδ2+ T Cells That Efficiently Target Breast Carcinoma Cells in the Presence of Bisphosphonate |
| Q92438871 | Analysis of macaque BTN3A genes and transcripts in the extended MHC: conserved orthologs of human γδ T cell modulators |
| Q41578214 | Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma. |
| Q90430104 | Anti-CD3 Fab Fragments Enhance Tumor Killing by Human γδ T Cells Independent of Nck Recruitment to the γδ T Cell Antigen Receptor |
| Q33920919 | Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug |
| Q36194639 | Anti-lymphoma effect of gammadelta T cells |
| Q46589194 | Anti-tumor cytotoxicity of gammadelta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma |
| Q38051730 | Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside |
| Q37729133 | Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies |
| Q37794160 | Anticancer Properties of Zoledronic Acid |
| Q24675038 | Antigens in tea-beverage prime human Vγ2Vδ2 T cells in vitro and in vivo for memory and nonmemory antibacterial cytokine responses |
| Q40620344 | Antitumor effects of minodronate, a third-generation nitrogen-containing bisphosphonate, in synergy with γδT cells in human glioblastoma in vitro and in vivo |
| Q64105155 | Aquatic Exercise at Thermoneutral Water Temperature Enhances Antitumor Immune Responses |
| Q91675416 | Assessment of Immune Response Following Dendritic Cell-Based Immunotherapy in Pediatric Patients With Relapsing Sarcoma |
| Q38149725 | At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies |
| Q38151057 | At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias |
| Q36040498 | Azathioprine therapy selectively ablates human Vδ2⁺ T cells in Crohn's disease. |
| Q50420977 | BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC). |
| Q37380386 | BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia |
| Q40070853 | BTN3A1 Discriminates γδ T Cell Phosphoantigens from Nonantigenic Small Molecules via a Conformational Sensor in Its B30.2 Domain |
| Q40115139 | Bacillus Calmette-Guérin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells |
| Q98735436 | Beneficial Effect of Antibiotics and Microbial Metabolites on Expanded Vδ2Vγ9 T Cells in Hepatocellular Carcinoma Immunotherapy |
| Q38848635 | Butyrophilin 3A (BTN3A, CD277)-specific antibody 20.1 differentially activates Vγ9Vδ2 TCR clonotypes and interferes with phosphoantigen activation |
| Q48359042 | Butyrophilin 3A/CD277-Dependent Activation of Human γδ T Cells: Accessory Cell Capacity of Distinct Leukocyte Populations. |
| Q27685257 | Butyrophilin 3A1 binds phosphorylated antigens and stimulates human γδ T cells |
| Q28660812 | Butyrophilin 3A1 plays an essential role in prenyl pyrophosphate stimulation of human Vγ2Vδ2 T cells |
| Q90187881 | Butyrophilin-2A1 Directly Binds Germline-Encoded Regions of the Vγ9Vδ2 TCR and Is Essential for Phosphoantigen Sensing |
| Q54268399 | Butyrophilin3A proteins and Vγ9Vδ2 T cell activation. |
| Q50308633 | Butyrophilins: an important new element of resistance |
| Q92853203 | CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy |
| Q26782520 | CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity |
| Q48331916 | CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells |
| Q35750453 | Can Zoledronic Acid be Beneficial for Promoting Tumor Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy? |
| Q38283536 | Cancer Immunotherapy Using γδT Cells: Dealing with Diversity |
| Q97653023 | Cancer immunotherapy with γδ T cells: many paths ahead of us |
| Q34493921 | Characterization of human γδ T lymphocytes infiltrating primary malignant melanomas |
| Q34769652 | Chemotherapy sensitizes colon cancer initiating cells to Vγ9Vδ2 T cell-mediated cytotoxicity |
| Q35208161 | Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours |
| Q98465659 | Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human Vγ2Vδ2 T Cells |
| Q37127038 | Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid. |
| Q46568857 | Complementary function of gamma delta T-lymphocytes and dendritic cells in the response to isopentenyl-pyrophosphate and lipopolysaccharide antigens |
| Q44952617 | Contribution of complementarity-determining region 3 of the T-cell receptor Vdelta2 chain to the recognition of aminobisphosphonates by human gammadelta T-cells |
| Q33554677 | Cord blood Vγ2Vδ2 T cells provide a molecular marker for the influence of pregnancy-associated malaria on neonatal immunity |
| Q90681174 | Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors |
| Q47100174 | Current Advances in γδ T Cell-Based Tumor Immunotherapy |
| Q49829282 | Current Status of Gene Engineering Cell Therapeutics |
| Q60241555 | Cytomegalovirus and tumor stress surveillance by binding of a human γδ T cell antigen receptor to endothelial protein C receptor |
| Q38217512 | Cytotoxic and regulatory properties of circulating Vδ1+ γδ T cells: a new player on the cell therapy field? |
| Q39092574 | Cytotoxic human peripheral blood-derived γδT cells kill glioblastoma cell lines: implications for cell-based immunotherapy for patients with glioblastoma |
| Q33436859 | DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells |
| Q55279130 | Decitabine Enhances Vγ9Vδ2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells via the NKG2DL-NKG2D Axis. |
| Q27026152 | Defining the nature of human γδ T cells: a biographical sketch of the highly empathetic |
| Q37344573 | Definition of APC presentation of phosphoantigen (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate to Vgamma2Vdelta 2 TCR. |
| Q36199422 | Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity |
| Q64060735 | Derivation of mimetic γδ T cells endowed with cancer recognition receptors from reprogrammed γδ T cell |
| Q40053061 | Differentiating Immune Cell Targets in Gut-Associated Lymphoid Tissue for HIV Cure. |
| Q50550722 | Distinctive features of tumor-infiltrating γδ T lymphocytes in human colorectal cancer. |
| Q27021646 | Diversity of γδ T-cell antigens |
| Q35046087 | Do γδ T cells predict osteonecrosis of the jaw? |
| Q46169443 | Dual Face of Vγ9Vδ2-T Cells in Tumor Immunology: Anti- versus Pro-Tumoral Activities |
| Q46485959 | Dysregulation of the host mevalonate pathway during early bacterial infection activates human TCR gamma delta cells |
| Q52367095 | Early Reconstitution of NK and γδ T Cells and Its Implication for the Design of Post-Transplant Immunotherapy. |
| Q24321574 | Ecto-F1-ATPase and MHC-class I close association on cell membranes |
| Q34428768 | Ecto-F₁-ATPase: a moonlighting protein complex and an unexpected apoA-I receptor |
| Q41061926 | Editorial: "Recent Advances in Gamma/Delta T Cell Biology: New Ligands, New Functions, and New Translational Perspectives". |
| Q54626514 | Editorial: Vγ9Vδ2 T cells: triple costimulation goes the distance. |
| Q36750128 | Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report |
| Q35090079 | Effector Vγ9Vδ2 T cells dominate the human fetal γδ T-cell repertoire |
| Q45296414 | Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. |
| Q37441693 | Effects of RANKL-Targeted Therapy in Immunity and Cancer |
| Q96303605 | Emerging Challenges of Preclinical Models of Anti-tumor Immunotherapeutic Strategies Utilizing Vγ9Vδ2 T Cells |
| Q26781175 | Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy |
| Q90044346 | Engineering γδT cells limits tonic signaling associated with chimeric antigen receptors |
| Q44653216 | Enhancement of BCG-induced Th1 immune response through Vgamma9Vdelta2 T cell activation with non-peptidic drugs |
| Q37655345 | Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation |
| Q64103688 | Evaluating in vivo efficacy - toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells |
| Q64057109 | Ex Vivo Expanded Human Vγ9Vδ2 T-Cells Can Suppress Epithelial Ovarian Cancer Cell Growth |
| Q37162910 | Ex vivo restimulation of human PBMC expands a CD3+CD4-CD8- γδ+ T cell population that can confound the evaluation of CD4 and CD8 T cell responses to vaccination. |
| Q55008660 | Expansion of Gammadelta T Cells from Cord Blood: A Therapeutical Possibility. |
| Q39585660 | Expansion of human peripheral blood γδ T cells using zoledronate |
| Q47666620 | Expansion of human γδ T cells for adoptive immunotherapy using a bisphosphonate prodrug |
| Q39602547 | Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens |
| Q41981818 | Expression of non-secreted IL-4 is associated with HDAC inhibitor-induced cell death, histone acetylation and c-Jun regulation in human gamma/delta T-cells |
| Q55111474 | Fish Lymphocytes: An Evolutionary Equivalent of Mammalian Innate-Like Lymphocytes? |
| Q38352469 | Five Layers of Receptor Signaling in γδ T-Cell Differentiation and Activation |
| Q35156294 | Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo |
| Q57244549 | Functional Expression of NOD2 in Freshly Isolated Human Peripheral Blood γδ T Cells |
| Q97644530 | Galectin-3 Released by Pancreatic Ductal Adenocarcinoma Suppresses γδ T Cell Proliferation but Not Their Cytotoxicity |
| Q34975891 | Gamma interferon secretion by human Vgamma2Vdelta2 T cells after stimulation with antibody against the T-cell receptor plus the Toll-Like receptor 2 agonist Pam3Cys |
| Q33825327 | Gammadelta T cell immune manipulation during chronic phase of simian-human immunodeficiency virus infection [corrected] confers immunological benefits |
| Q37587832 | Gammadelta T cells as immune effectors against high-grade gliomas |
| Q38945041 | HIV infection: focus on the innate immune cells. |
| Q37072016 | HMBPP Analog Prodrugs Bypass Energy-Dependent Uptake To Promote Efficient BTN3A1-Mediated Malignant Cell Lysis by Vγ9Vδ2 T Lymphocyte Effectors |
| Q34018807 | HMGB1 and cord blood: its role as immuno-adjuvant factor in innate immunity |
| Q42132237 | HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition |
| Q37152701 | Hallmarks of Tissue-Resident Lymphocytes |
| Q37409283 | Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma |
| Q27027547 | Harnessing the power of Vδ2 cells in cancer immunotherapy |
| Q36734208 | Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate |
| Q48232215 | Heteromeric interactions regulate butyrophilin (BTN) and BTN-like molecules governing γδ T cell biology |
| Q33455830 | Highly active microbial phosphoantigen induces rapid yet sustained MEK/Erk- and PI-3K/Akt-mediated signal transduction in anti-tumor human gammadelta T-cells |
| Q42740131 | How to exploit stress-related immunity against Hodgkin's lymphoma: Targeting ERp5 and ADAM sheddases. |
| Q39396311 | Human Vδ2 versus non-Vδ2 γδ T cells in antitumor immunity. |
| Q50927130 | Human cord blood γδ T cells expressing public Vγ2 chains dominate the response to bisphosphonate plus interleukin-15. |
| Q35738915 | Human gamma delta T cells: Evolution and ligand recognition |
| Q36908780 | Human gamma delta T cells: candidates for the development of immunotherapeutic strategies |
| Q41812496 | Human gamma delta T lymphocytes for immunotherapeutic strategies against cancer |
| Q45002846 | Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity |
| Q54940475 | Human γδ T-Cells: From Surface Receptors to the Therapy of High-Risk Leukemias. |
| Q38027044 | Human γδ T-cell responses in infection and immunotherapy: common mechanisms, common mediators? |
| Q37714642 | Human γδT-cell subsets and their involvement in tumor immunity. |
| Q38171917 | Hunting for clinical translation with innate-like immune cells and their receptors |
| Q38040743 | IL-17-producing γδ T cells and innate lymphoid cells |
| Q47217155 | IL-21 promotes the development of a CD73-positive Vγ9Vδ2 T cell regulatory population. |
| Q47422433 | IL-23 Activated γδ T Cells Affect Th17 Cells and Regulatory T Cells by Secreting IL-21 in Children with Primary Nephrotic Syndrome |
| Q48031093 | IL-33-expanded human Vγ9Vδ2 T cells have anti-lymphoma effect in a mouse tumor model |
| Q33322644 | Identification of human T cell receptor gammadelta-recognized epitopes/proteins via CDR3delta peptide-based immunobiochemical strategy |
| Q92757627 | Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells |
| Q38752243 | Immune-mediated syndromes following intravenous bisphosphonate therapy |
| Q38108390 | Immunologic microenvironment and personalized treatment in multiple myeloma. |
| Q36871994 | Immunomodulating role of bisphosphonates on human gamma delta T cells: an intriguing and promising aspect of their antitumour activity |
| Q37822747 | Immunotherapy targeting colon cancer stem cells |
| Q39317720 | Impaired function of gamma-delta lymphocytes in melanoma patients |
| Q55311835 | Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer. |
| Q87518258 | In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes |
| Q40076011 | In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma |
| Q43057295 | In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients |
| Q52780147 | In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment. |
| Q35889808 | Indirect stimulation of human Vγ2Vδ2 T cells through alterations in isoprenoid metabolism |
| Q39588867 | Inhibition of human gamma delta [corrected] T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer |
| Q53008599 | Inhibition of human γδ T cell proliferation and effector functions by neutrophil serine proteases. |
| Q37737540 | Insights into Local Tumor Microenvironment Immune Factors Associated with Regression of Cutaneous Melanoma Metastases by Mycobacterium bovis Bacille Calmette-Guérin |
| Q47346919 | Integrated immune responses to infection - cross-talk between human gammadelta T cells and dendritic cells |
| Q64275741 | Interleukin-18 in Health and Disease |
| Q84803680 | Interplay of T-cell receptor and interleukin-2 signalling in Vγ2Vδ2 T-cell cytotoxicity |
| Q37703392 | Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer. |
| Q37605637 | Inversion of the Vδ1 to Vδ2 γδ T cell ratio in CVID is not restored by IVIg and is associated with immune activation and exhaustion |
| Q37038276 | Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma |
| Q24339540 | Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset |
| Q36853886 | L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer |
| Q34372167 | Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy |
| Q38013197 | Licensing of killer dendritic cells in mouse and humans: functional similarities between IKDC and human blood γδ T-lymphocytes |
| Q97692776 | Ligand recognition by the γδ TCR and discrimination between homeostasis and stress conditions |
| Q39758159 | Lipophilic pyridinium bisphosphonates: potent gammadelta T cell stimulators |
| Q40106388 | Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. |
| Q34395222 | Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells |
| Q61727663 | Mapping of γ/δ T cells reveals Vδ2+ T cells resistance to senescence |
| Q36883879 | Mechanisms of the antitumor activity of human Vγ9Vδ2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma. |
| Q34560345 | Metabolic engineering of Salmonella vaccine bacteria to boost human Vγ2Vδ2 T cell immunity. |
| Q40065267 | Metabolism in Immune Cell Differentiation and Function. |
| Q57300154 | Mevalonate Metabolism in Cancer Stemness and Trained Immunity |
| Q46592108 | Mevalonate metabolism governs cancer immune surveillance. |
| Q28208141 | Microbial isoprenoid biosynthesis and human gammadelta T cell activation |
| Q55237064 | Molecular Determinants of Target Cell Recognition by Human γδ T Cells. |
| Q34819275 | Molecules and Mechanisms Implicated in the Peculiar Antigenic Activation Process of Human Vγ9Vδ2 T Cells |
| Q50932570 | Monocytes and γδ T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial. |
| Q37122974 | Mycobacteria and innate cells: critical encounter for immunogenicity |
| Q49333274 | NK Cells and γδT Cells for Relapse Protection After Allogeneic Hematopoietic Cell Transplantation (HCT). |
| Q39798606 | NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human γδ T cells: Modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitors |
| Q92444661 | Nanoformulated Zoledronic Acid Boosts the Vδ2 T Cell Immunotherapeutic Potential in Colorectal Cancer |
| Q90534741 | New Insights Into the Regulation of γδ T Cells by BTN3A and Other BTN/BTNL in Tumor Immunity |
| Q37481361 | New frontiers in cell-based immunotherapy of cancer. |
| Q34487392 | Nuclear hormone receptors put immunity on sterols |
| Q38818271 | Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo. |
| Q34502899 | Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment |
| Q36348587 | Peripheral blood T-cell signatures from high-resolution immune phenotyping of γδ and αβ T-cells in younger and older subjects in the Berlin Aging Study II |
| Q42183397 | Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. |
| Q36334874 | Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma |
| Q38934681 | Phenotype and regulation of immunosuppressive Vδ2-expressing γδ T cells |
| Q37226209 | Phenotypic and functional alterations of Vgamma2Vdelta2 T cell subsets in patients with active nasopharyngeal carcinoma. |
| Q50708147 | Phenotypic characterization and prognostic impact of circulating γδ and αβ T-cells in metastatic malignant melanoma. |
| Q34970077 | Phosphoantigen Presentation to TCR γδ Cells, a Conundrum Getting Less Gray Zones |
| Q40093467 | Phosphoantigen-induced conformational change of butyrophilin 3A1 (BTN3A1) and its implication on Vγ9Vδ2 T cell activation |
| Q37226687 | Photoaffinity antigens for human gammadelta T cells |
| Q38496996 | Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients |
| Q34652408 | Plasticity of γδ T Cells: Impact on the Anti-Tumor Response |
| Q57300020 | Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression |
| Q35896206 | Potential of human gammadelta T lymphocytes for immunotherapy of cancer |
| Q38052064 | Potential of human γδ T cells for immunotherapy of osteosarcoma |
| Q34162359 | Potential pathophysiological mechanisms in osteonecrosis of the jaw. |
| Q64060934 | Preferential Infiltration of Unique Vγ9Jγ2-Vδ2 T Cells Into Glioblastoma Multiforme |
| Q34595188 | Preferential Th1 cytokine profile of phosphoantigen-stimulated human Vγ9Vδ2 T cells. |
| Q38728528 | Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody. |
| Q33832188 | Prolonged (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate-driven antimicrobial and cytotoxic responses of pulmonary and systemic Vgamma2Vdelta2 T cells in macaques |
| Q40355238 | Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab |
| Q38890450 | Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy. |
| Q57024595 | Protective Role of T Cells in Different Pathogen Infections and Its Potential Clinical Application |
| Q41450925 | RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma. |
| Q41807960 | Radiation-induced DNA damage and repair in human gammadelta and alphabeta T-lymphocytes analysed by the alkaline comet assay |
| Q44898932 | Recognition of nonpeptide antigens by human V gamma 9V delta 2 T cells requires contact with cells of human origin |
| Q26823185 | Regeneration of stalled immune responses to transformed and infected cells using γδ T cells |
| Q92405201 | Regulatory Interactions Between Neutrophils, Tumor Cells and T Cells |
| Q38787725 | Regulatory and effector functions of gamma-delta (γδ) T cells and their therapeutic potential in adoptive cellular therapy for cancer |
| Q88008277 | Regulatory functions of γδ T cells |
| Q37731978 | Repertoire development and the control of cytotoxic/effector function in human gammadelta T cells |
| Q37854072 | Requisite considerations for successful adoptive immunotherapy with engineered T-lymphocytes using tumor antigen-specific T-cell receptor gene transfer |
| Q37279963 | RhoB Mediates Phosphoantigen Recognition by Vγ9Vδ2 T Cell Receptor |
| Q36388793 | Role of apolipoproteins in gammadelta and NKT cell-mediated innate immunity. |
| Q27026700 | Role of non-conventional T lymphocytes in respiratory infections: the case of the pneumococcus |
| Q38093573 | Roles of γδ T cells in the pathogenesis of autoimmune diseases |
| Q28287583 | Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue? |
| Q35000371 | Sensing of Pyrophosphate Metabolites by Vγ9Vδ2 T Cells. |
| Q34077388 | Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: implications for immunotherapy |
| Q36845046 | Sensor Function for Butyrophilin 3A1 in Prenyl Pyrophosphate Stimulation of Human Vγ2Vδ2 T Cells |
| Q37018333 | Significance and impact of bisphosphonate-induced acute phase responses |
| Q27010451 | Six-of-the-best: unique contributions of γδ T cells to immunology |
| Q35935862 | Skewed Differentiation of Circulating Vγ9Vδ2 T Lymphocytes in Melanoma and Impact on Clinical Outcome |
| Q39807695 | Specific requirements for Vgamma9Vdelta2 T cell stimulation by a natural adenylated phosphoantigen. |
| Q40953833 | Stress-related and homeostatic cytokines regulate Vγ9Vδ2 T-cell surveillance of mevalonate metabolism. |
| Q36920135 | Suppression of CYP2B induction by alendronate-mediated farnesyl diphosphate synthase inhibition in primary cultured rat hepatocytes |
| Q26865650 | T cell recognition of non-peptidic antigens in infectious diseases |
| Q38398684 | T lymphocyte regulation by mevalonate metabolism. |
| Q90290705 | TRAIL-Receptor 4 Modulates γδ T Cell-Cytotoxicity Toward Cancer Cells |
| Q92304043 | Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions |
| Q38179172 | Targeting gamma delta T cells for cancer immunotherapy: bench to bedside |
| Q28659468 | Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer |
| Q53238656 | Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells. |
| Q42211743 | The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells. |
| Q27682926 | The Intracellular B30.2 Domain of Butyrophilin 3A1 Binds Phosphoantigens to Mediate Activation of Human Vγ9Vδ2 T Cells |
| Q28069991 | The Role of γδ T Cells in Fibrotic Diseases |
| Q26765027 | The Role of γδ T Cells in Systemic Lupus Erythematosus |
| Q38370910 | The T cell antigen receptor: the Swiss army knife of the immune system. |
| Q46483041 | The Vgamma2/Vdelta2 T-cell repertoire in Macaca fascicularis: functional responses to phosphoantigen stimulation by the Vgamma2/Jgamma1.2 subset |
| Q34741552 | The Vγ9Vδ2 T Cell Antigen Receptor and Butyrophilin-3 A1: Models of Interaction, the Possibility of Co-Evolution, and the Case of Dendritic Epidermal T Cells |
| Q37847339 | The backbone of progress--preclinical studies and innovations with zoledronic acid |
| Q24684244 | The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins |
| Q50892187 | The butyrophilin 3A1 intracellular domain undergoes a conformational change involving the juxtamembrane region. |
| Q42155981 | The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. |
| Q37808268 | The crossover of bisphosphonates to cancer therapy |
| Q92628379 | The features of circulating and tumor-infiltrating γδ T cells in melanoma patients display critical perturbations with prognostic impact on clinical outcome |
| Q37172099 | The invisible arm of immunity in common cancer chemoprevention agents |
| Q38016451 | The multifunctionality of human Vγ9Vδ2 γδ T cells: clonal plasticity or distinct subsets? |
| Q37359263 | The potential role of CD16+ Vγ2Vδ2 T cell-mediated antibody-dependent cell-mediated cytotoxicity in control of HIV type 1 disease |
| Q26859775 | The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy |
| Q60241510 | The γδTCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness |
| Q59806979 | Tissue Adaptations of Memory and Tissue-Resident Gamma Delta T Cells |
| Q54219852 | Towards Deciphering the Hidden Mechanisms That Contribute to the Antigenic Activation Process of Human Vγ9Vδ2 T Cells. |
| Q93162748 | Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies |
| Q38839878 | Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors |
| Q37096879 | Treatment of breast cancer with bone metastasis: bisphosphonate treatment - current and future |
| Q44732034 | Tripartite immune cell co-operation in the Bacillus Calmette Guérin-induced activation of γδ T cells |
| Q42086300 | Tumor cell recognition by γδ T lymphocytes: T-cell receptor vs. NK-cell receptors |
| Q38287973 | Tumor-Infiltrating γδ T Lymphocytes: Pathogenic Role, Clinical Significance, and Differential Programing in the Tumor Microenvironment. |
| Q37706085 | Tumor-activated TCRγδ⁺ T cells from gastric cancer patients induce the antitumor immune response of TCRαβ⁺ T cells via their antigen-presenting cell-like effects. |
| Q40618363 | Uncoupling between Immunological Synapse Formation and Functional Outcome in Human γδ T Lymphocytes |
| Q37990046 | Understanding the complexity of γδ T-cell subsets in mouse and human |
| Q52657143 | Valproic Acid Combined with Zoledronate Enhance γδ T Cell-Mediated Cytotoxicity against Osteosarcoma Cells via the Accumulation of Mevalonate Pathway Intermediates. |
| Q46808881 | Vdelta2 T-lymphocyte responses in cord blood samples from Italy and Côte d'Ivoire |
| Q34749889 | Vgamma2Vdelta2 T Cell Receptor recognition of prenyl pyrophosphates is dependent on all CDRs |
| Q36237901 | Vgamma9Vdelta2 T cell-mediated non-cytolytic antiviral mechanisms and their potential for cell-based therapy |
| Q92573018 | Vitamin C promotes the proliferation and effector functions of human γδ T cells |
| Q42187331 | Vγ2Vδ2 T cell Costimulation Increases NK cell Killing of Monocyte-derived Dendritic Cells |
| Q42237075 | Vγ9 and Vδ2 T cell antigen receptor genes and butyrophilin 3 (BTN3) emerged with placental mammals and are concomitantly preserved in selected species like alpaca (Vicugna pacos). |
| Q98177693 | Vγ9Vδ2 T Cells Activation Through Phosphoantigens Can Be Impaired by a RHOB Rerouting in Lung Cancer |
| Q40150564 | Vγ9Vδ2 T cell activation by strongly agonistic nucleotidic phosphoantigens. |
| Q37876363 | Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside. |
| Q42214986 | Vγ9Vδ2 TCR-activation by phosphorylated antigens requires butyrophilin 3 A1 (BTN3A1) and additional genes on human chromosome 6. |
| Q55310862 | Zoledronate Triggers Vδ2 T Cells to Destroy and Kill Spheroids of Colon Carcinoma: Quantitative Image Analysis of Three-Dimensional Cultures. |
| Q40252845 | Zoledronate can induce colorectal cancer microenvironment expressing BTN3A1 to stimulate effector γδ T cells with antitumor activity. |
| Q38986536 | Zoledronic acid causes γδ T cells to target monocytes and down-modulate inflammatory homing |
| Q39558094 | Zoledronic acid enhances Vδ2 T-lymphocyte antitumor response to human glioma cell lines |
| Q36708315 | Zoledronic acid in the management of metastatic bone disease. |
| Q59242355 | Zoledronic acid modulates maturation of human monocyte-derived dendritic cells |
| Q40213985 | Zoledronic acid renders human M1 and M2 macrophages susceptible to Vδ2(+) γδ T cell cytotoxicity in a perforin-dependent manner. |
| Q47270508 | Zoledronic acid sensitizes rhabdomyosarcoma cells to cytolysis mediated by human γδ T cells |
| Q39424272 | Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug |
| Q36803818 | Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells |
| Q36429414 | Zoledronic acid: past, present and future roles in cancer treatment |
| Q26995102 | γδ T Cell Immunotherapy-A Review |
| Q37836561 | γδ T cell receptor ligands and modes of antigen recognition |
| Q35799192 | γδ T cells and epigenetic drugs: A useful merger in cancer immunotherapy? |
| Q37576001 | γδ T cells and their potential for immunotherapy |
| Q38262257 | γδ T cells as a potential tool in colon cancer immunotherapy |
| Q34496948 | γδ T cells cross-link innate and adaptive immunity in Mycobacterium tuberculosis infection. |
| Q27021705 | γδ T cells for cancer immunotherapy: A systematic review of clinical trials |
| Q38602555 | γδ T cells in cancer |
| Q90783584 | γδ T cells in cancer: a small population of lymphocytes with big implications |
| Q37870836 | γδ T-cell immunotherapy for lung cancer. |
| Q35634919 | γδ T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-αβ+/CD19+ lymphocytes |
| Q92005867 | γδ T-cell responses during HIV infection and antiretroviral therapy |
| Q37871905 | γδ T-cells: cross-talk between innate and adaptive immunity |
| Q85818563 | γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia |
| Q38271585 | γδ T Lymphocytes as a First Line of Immune Defense: Old and New Ways of Antigen Recognition and Implications for Cancer Immunotherapy |